(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 September 2011 (22.09.2011)

PCT

(10) International Publication Number
WO 2011/115943 A1

(51) International Patent Classification:
C07D 403/04 (2006.01) *A61P 11/00* (2006.01)
A61K 31/505 (2006.01)

(21) International Application Number:
PCT/US2011/028433

(22) International Filing Date:
15 March 2011 (15.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/314,421 16 March 2010 (16.03.2010) US

(71) Applicant *(for all designated States except US)*: **AVENTIS PHARMACEUTICALS INC.** [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08822 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HARRIS, Keith John** [GB/US]; Sanofi-Aventis U.S., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US). **AGUIAR, Joacy C.** [BR/US]; Sanofi-Aventis U.S., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US). **SHUM, Patrick Wai-Kwok** [US/US]; Sanofi-Aventis U.S., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US). **ZHAO, Zhicheng** [US/US]; Sanofi-Aventis U.S., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US). **POLI, Gregory B.** [US/US]; Sanofi-Aventis U.S., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US). **STOKLOSA, Gregory T.** [CA/US]; Sanofi-Aventis U.S., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US). **CHOI-SLEDESKI, Yong-Mi** [US/US]; Sanofi-Aventis U.S., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US). **REILING, Stephan** [DE/US]; Sanofi-Aventis U.S., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US).

(74) Agents: **ORT, Ronald G.** et al.; Sanofi-Aventis U.S. Inc., 1041 Route 202-206, Mail Code: D-303A, Bridgewater, New Jersey 08807 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: A SUBSTITUTED PYRIMIDINE AS A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST



(I)

(57) Abstract: The present invention is directed to a 2,6-substituted-4-monosubstitutedamino-pyrinudine compound of formula (I) as set forth herein, or an enantiomer thereof, or an ester prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.

WO 2011/115943 A1